Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study

Authors:

Abstract
No abstract available
Funding Information
  • Astellas Pharma US Inc
  • Astellas Pharma
  • Pfizer
  • Pfizer Inc

This publication has 18 references indexed in Scilit: